sigvotatug vedotin + pembrolizumab

Tenant **Sigvotatug vedotin + pembrolizumab** is an investigational combination therapy evaluated for the treatment of advanced solid tumors and non-small cell lung cancer (NSCLC). Sigvotatug vedotin is an antibody-drug conjugate (ADC) that targets integrin beta-6 (IB6), a tumor-associated membrane protein, and delivers a cytotoxic agent to cancer cells, thereby inducing cell death. Pembrolizumab is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor, enhancing T-cell mediated antitumor immunity. This combination is being studied for additive or synergistic effects in improving clinical outcomes in NSCLC and other solid tumors[1][2][3][4][5][6].